Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice-Reference-Cited by-同舟云学术

Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice

Published:2022-11 Issue:11 Volume:4 Page:100573
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

Kunst Roni F.,de Waart Dirk R.,Wolters Frank,Duijst Suzanne,Vogels Esther W.^ORCID,Bolt Isabelle,Verheij Joanne,Beuers Ulrich^ORCID,Oude Elferink Ronald P.J.^ORCID,van de Graaf Stan F.J.^ORCID

Funder

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

European Research Council

Netherlands Organisation for Health Research and Development

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Immunology and Allergy,Internal Medicine

Reference25 articles.

1. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis;Baghdasaryan;J Hepatol,2016

2. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation;Graffner;Aliment Pharmacol Ther,2016

3. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study;Hegade;Lancet,2017

4. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis;Mayo;Hepatol Commun,2019

5. BAT117213: ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial;Hegade;BMC Gastroenterol,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials;Expert Opinion on Emerging Drugs;2024-07-04

2. Design and development of novel self-assembled catechol-modified bile acid conjugates as pH-responsive apical sodium-dependent bile acid transporter targeting nanoparticles;Biomaterials;2024-07

3. SMARCA4 (BRG1) activates ABCC3 transcription to promote hepatocellular carcinogenesis;Life Sciences;2024-06

4. Molecular insights into experimental models and therapeutics for cholestasis;Biomedicine & Pharmacotherapy;2024-05

5. Sodium/bile acid co-transporter inhibitors currently in preclinical or early clinical development for the treatment of primary biliary cholangitis;Expert Opinion on Investigational Drugs;2024-04-24